Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion

NCT05794464 is registered in ClinicalTrials.gov with University Hospital Ostrava as lead sponsor.

NCT NCT05794464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05794464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
Lead sponsor
University Hospital Ostrava
Phase
Not applicable
Overall status
Recruiting
Start date
May 1, 2023
Completion date
August 31, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, paroxysmal or persistent